Exagen (XGN) Debt to Equity (2018 - 2025)
Historic Debt to Equity for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $1.26.
- Exagen's Debt to Equity fell 1963.91% to $1.26 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.26, marking a year-over-year decrease of 1963.91%. This contributed to the annual value of $2.12 for FY2024, which is 14703.43% up from last year.
- Exagen's Debt to Equity amounted to $1.26 in Q3 2025, which was down 1963.91% from $1.09 recorded in Q2 2025.
- In the past 5 years, Exagen's Debt to Equity ranged from a high of $3.27 in Q1 2025 and a low of $0.26 during Q1 2021
- Over the past 5 years, Exagen's median Debt to Equity value was $0.71 (recorded in 2023), while the average stood at $0.93.
- As far as peak fluctuations go, Exagen's Debt to Equity plummeted by 4947.54% in 2021, and later soared by 23463.38% in 2025.
- Quarter analysis of 5 years shows Exagen's Debt to Equity stood at $0.32 in 2021, then skyrocketed by 110.88% to $0.68 in 2022, then increased by 25.91% to $0.86 in 2023, then surged by 147.03% to $2.12 in 2024, then tumbled by 40.4% to $1.26 in 2025.
- Its last three reported values are $1.26 in Q3 2025, $1.09 for Q2 2025, and $3.27 during Q1 2025.